Souhaitez-vous accéder aux communiqués récents ?

On Aug 26, 2025, EHang cut its 2025 revenue forecast nearly in half, prompting Morgan Stanley downgrades. ADRs fell $1.34, or 7.5%, to $16.45.

Allegedly, RxSight hid adoption issues and overstated demand, later slashing guidance and revealing weak sales, causing its stock to drop nearly 38%.

RxSight allegedly overstated product demand while facing adoption issues, then cut guidance and revealed weak sales, causing shares to plunge 38%.

Visa allegedly failed to comply with antitrust laws and lacked effective compliance controls, making its statements misleading and causing investor harm.

RxSight suit claims adoption issues and overstated demand. After July 2025 guidance cut, shares plunged ~38%.

The complaint alleges Flywire overstated revenue growth while downplaying visa and permit risks, later revealed as results and guidance fell short.

The complaint alleges RxSight overstated demand and concealed adoption issues, then cut guidance, causing its stock to drop nearly 38%.

The lawsuit alleges Lineage misled investors in its IPO registration statement about demand and trends, while hiding a sustained downturn.

The lawsuit alleges Neogen misled investors on 3M integration, downplaying issues that led to weak results, guidance cuts, and steep stock declines.

iRobot allegedly misled investors on post-Amazon deal stability; poor 2024 results and viability doubts led to a 51.6% stock drop in two trading days.